June 3, 2020Open Access

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

Key Points

Key points are not available for this paper at this time.

Abstract

Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Minard‐Colin et al. (Wed,) studied this question.

synapsesocial.com/papers/690227904b9c5ba3f254aa74 — DOI: https://doi.org/10.1056/nejmoa1915315

Authors

Véronique Minard‐Colin

Inserm

Anne Aupérin

Inserm

Marta Pillon

University of Padua

Journals

New England Journal of Medicine

Actions

Institutions

Inserm

University of Southern California

National Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion